Use of Renin-Angiotensin Inhibitors in People with Renal Artery Stenosis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: People with atherosclerotic renal artery stenosis may benefit from renin-angiotensin inhibitors, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers, but little is known about the factors associated with their use. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Cardiovascular Outcomes in Renal Atherosclerotic Lesions study (ClinicalTrials.gov identified: NCT00081731) is a prospective, international, multicenter clinical trial that randomly assigned participants with atherosclerotic renal artery stenosis who received optimal medical therapy to stenting versus no stenting from May 2005 through January 2010. At baseline, medication information was available from 853 of 931 randomly assigned participants. Kidney function was measured by serum creatinine-based eGFR at a core laboratory. RESULTS: Before randomization, renin-angiotensin inhibitors were used in 419 (49%) of the 853 participants. Renin-angiotensin inhibitor use was lower in those with CKD (eGFR<60 ml/min per 1.73 m(2)) (58% versus 68%; P=0.004) and higher in individuals with diabetes (41% versus 27%; P<0.001). Presence of bilateral renal artery stenosis or congestive heart failure was not associated with renin-angiotensin inhibitor use. Although therapy with renin-angiotensin inhibitors varied by study site, differences in rates of use were not related to the characteristics of the site participants. Participants receiving a renin-angiotensin inhibitor had lower systolic BP (mean ± SD, 148 ± 23 versus 152 ± 23 mmHg; P=0.003) and more often had BP at goal (30% versus 22%; P=0.01). CONCLUSIONS: Kidney function and diabetes were associated with renin-angiotensin inhibitor use. However, these or other clinical characteristics did not explain variability among study sites. Patients with renal artery stenosis who received renin-angiotensin inhibitor treatment had lower BP and were more likely to be at treatment goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Angiotensin inhibition in renovascular disease: A population-based cohort study
Hackam, D. G., Duong-Hua, M. L., Mamdani, M., Li, P., Tobe, S. W., Spence, J. D., & Garg, A. X. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.05.013 · Cited by 143
Research works printed but not linked: 33
- Hansen, 2002, Prevalence of renovascular disease in the elderly:A population-based study., J Vasc Surg, 36, 443, 10.1067/mva.2002.127351 · DOI · Paper page
- Kalra, 2005, Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis., Kidney Int, 68, 293, 10.1111/j.1523-1755.2005.00406.x · DOI · Paper page
- Kalra, 2010, Atherosclerotic renovascular disease in the United States., Kidney Int, 77, 37, 10.1038/ki.2009.406 · DOI
- Lao, 2011, Atherosclerotic renal artery stenosis—diagnosis and treatment., Mayo Clin Proc, 86, 649, 10.4065/mcp.2011.0181 · DOI
- Long, 2004, How does angiotensin II cause renal injury?, Hypertension, 43, 722, 10.1161/01.HYP.0000120964.22281.3e · doi:10.1161/01.hyp.0000120964.22281.3e
- Lonn, 1994, Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection., Circulation, 90, 2056, 10.1161/01.CIR.90.4.2056 · DOI · Paper page
- Johnson, 2008, Pathogenesis of essential hypertension: Historical paradigms and modern insights., J Hypertens, 26, 381, 10.1097/HJH.0b013e3282f29876 · DOI
- Tokuyama, 2002, Differential regulation of elevated renal angiotensin II in chronic renal ischemia., Hypertension, 40, 34, 10.1161/01.HYP.0000022060.13995.ED · doi:10.1161/01.hyp.0000022060.13995.ed
- Montecucco, 2009, The renin-angiotensin system modulates inflammatory processes in atherosclerosis: Evidence from basic research and clinical studies., Mediators Inflamm, 2009, 752406, 10.1155/2009/752406 · DOI
- Akers, 2000, Renin-angiotensin system and sympathetic nervous system in cardiac pressure-overload hypertrophy., Am J Physiol Heart Circ Physiol, 279, H2797, 10.1152/ajpheart.2000.279.6.H2797 · DOI
- Hricik, 1983, Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney., N Engl J Med, 308, 373, 10.1056/NEJM198302173080706 · DOI · Paper page
- Bart, 1997, Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction., Am J Cardiol, 79, 1118, 10.1016/S0002-9149(97)00060-X · DOI
- van de Ven, 1998, Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease., Kidney Int, 53, 986, 10.1111/j.1523-1755.1998.00840.x · DOI
- Ahmed, 2002, Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: How concerned should we be by the rise in serum creatinine?, J Am Geriatr Soc, 50, 1297, 10.1046/j.1532-5415.2002.50321.x · DOI
- Chrysochou, 2012, Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease., Nephrol Dial Transplant, 27, 1403, 10.1093/ndt/gfr496 · DOI · Paper page
- Losito, 2005, Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition., Nephrol Dial Transplant, 20, 1604, 10.1093/ndt/gfh865 · DOI · Paper page
- Calhoun, 2008, Resistant hypertension: diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research., Circulation, 117, e510, 10.1161/CIRCULATIONAHA.108.189141 · DOI · Paper page
- Chobanian, 2003, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report., JAMA, 289, 2560, 10.1001/jama.289.19.2560 · DOI · Paper page
- Foley, 2007, End-stage renal disease in the United States: An update from the United States Renal Data System., J Am Soc Nephrol, 18, 2644, 10.1681/ASN.2007020220 · DOI · Paper page
- Guo, 2007, Atherosclerotic renovascular disease in older US patients starting dialysis, 1996 to 2001., Circulation, 115, 50, 10.1161/CIRCULATIONAHA.106.637751 · DOI
- de Silva, 2007, Epidemiology, associated factors, and prognostic outcomes of renal artery stenosis in chronic heart failure assessed by magnetic resonance angiography., Am J Cardiol, 100, 273, 10.1016/j.amjcard.2007.02.098 · DOI
- Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines., Circulation, 128, 1810, 10.1161/CIR.0b013e31829e8807 · DOI · Paper page
- de Mast, 2009, The prevalence of atherosclerotic renal artery stenosis in risk groups: A systematic literature review., J Hypertens, 27, 1333, 10.1097/HJH.0b013e328329bbf4 · DOI · Paper page
- Bourantas, 2012, Atherosclerotic disease of the abdominal aorta and its branches: Prognostic implications in patients with heart failure., Heart Fail Rev, 17, 229, 10.1007/s10741-011-9284-9 · DOI
- Cooper, 2006, Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial., Am Heart J, 152, 59, 10.1016/j.ahj.2005.09.011 · DOI · Paper page
- Wheatley, 2009, Revascularization versus medical therapy for renal-artery stenosis., N Engl J Med, 361, 1953, 10.1056/NEJMoa0905368 · DOI · Paper page
- Bax, 2009, Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: A randomized trial., Ann Intern Med, 150, 840, 10.7326/0003-4819-150-12-200906160-00119 · DOI · Paper page
- Ravid, 1993, Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients., Ann Intern Med, 118, 577, 10.7326/0003-4819-118-8-199304150-00001 · DOI · Paper page
- Mogensen, 2000, Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study., BMJ, 321, 1440, 10.1136/bmj.321.7274.1440 · DOI · Paper page
- Keyhani, 2008, Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits., Hypertension, 51, 1149, 10.1161/HYPERTENSIONAHA.107.107342 · DOI · Paper page
- Rocha-Singh, 2005, Evaluation of the safety and effectiveness of renal artery stenting after unsuccessful balloon angioplasty: The ASPIRE-2 study., J Am Coll Cardiol, 46, 776, 10.1016/j.jacc.2004.11.073 · DOI · Paper page
- Jaff, 2012, Significant reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: Results from the HERCULES trial., Catheter Cardiovasc Interv, 80, 343, 10.1002/ccd.24449 · DOI · Paper page
- Rocha-Singh, 2008, Renal artery stenting with noninvasive duplex ultrasound follow-up: 3-year results from the RENAISSANCE renal stent trial., Catheter Cardiovasc Interv, 72, 853, 10.1002/ccd.21749 · DOI
Cited by
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
Mazzolai, L., Teixido-Tura, G., Lanzi, S., Boc, V., Bossone, E., Brodmann, M., Bura-Rivière, A., De Backer, J., Deglise, S., Della Corte, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae179 · Cited by 993
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2017.07.018 · Cited by 963
Metadata
- Authors
- Evans, K. L., Tuttle, K. R., Folt, D. A., Dawson, T., Haller, S. T., Brewster, P. S., He, W., Jamerson, K., Dworkin, L. D., Cutlip, D. E., Murphy, T. P., D’Agostino, R. B., Henrich, W., & Cooper, C. J.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2014-07
- Volume
- 9
- Issue
- 7
- Pages
- 1199-1206
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2149633685
- Cited by
- 45
- References
- 4
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.